

Substitute for forms 1449A/PTO & 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTORNEY'S DKT NO. 033285-019	APPLICATION NO. Unassigned
	APPLICANT Rudolf WANK	
	FILING DATE October 20, 2002	GROUP Unassigned

U.S. PATENT DOCUMENTS				
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation Yes No	
/Z.S./	WO 9520349	A	PCT	01-27-1995		
	WO 9520649	A	PCT	08-03-1995		
	WO 9629394	A	PCT	09-26-1996		
	WO 9950393	A	PCT	10-07-1999		
	DE 19814701	A1	Germany (with English Abstract)	04-01-1998		
	DE 68925660	T2	Germany (with English Abstract)	06-02-1989		

NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/Z.S./	Takayama, T. et al., "Adoptive Immunotherapy to Lower Postsurgical Recurrence Rates of Hepatocellular Carcinoma: A Randomised Trial," Lancet (2000), Vol. 356, n. 9232, pp. 802-807.
/Z.S./	Stohl et al., Abstract, "Stimulation of human peripheral blood mononuclear cells with anti-CD3 monoclonal antibody vs. IL2: disparate effects on T cell-dependent B cell differentiation despite similar effects on generation of unrestricted cytolytic activity," PubMed 1395122, Clin. Immunol. Immunopathol., (1992), 65(1):30-8.
/Z.S./	Baxeavauis et al., Abstract, "Induction of anti-tumor lymphocytes in cancer patients after brief exposure to supernatants from cultures of anti-CD3-stimulated allogeneic lymphocytes," PubMed 9376269, Br. J. Cancer, (1997) 76(8), pp. 1072-1080.

Examiner Signature	/Zachary Skelding/	Date Considered	11/25/2007
-----------------------	--------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for forms 1449A/PTO & 1449B/PTO

SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKT NO.
033285-019

APPLICATION No.
10/687,913

APPLICANT
Rudolf WANK

FILING DATE
October 20, 2002

GROUP
Unassigned

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/Z.S./	van Leeuwen et al., "T cell antigen-receptor signal transduction," Curr. Opin. Immunol., (1999), 11:242-248.
/Z.S./	Sheehy et al., "HL-A LD (lymphocyte defined) typing: a rapid assay with primed lymphocytes," Science, (1975), 188:1308-1310.
/Z.S./	Wank et al., "High risk of squamous cell carcinoma for women with HLA-DQw3," Nature, (1991), 352:723-725.

Examiner Signature	/Zachary Skelding/	Date Considered	11/25/2007
--------------------	--------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.